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Methylation‑derived inflammatory measures
and lung cancer risk and survival
Naisi Zhao1, Mengyuan Ruan1, Devin C. Koestler2,3, Jiayun Lu4, Lucas A. Salas6, Karl T. Kelsey7,8,
Elizabeth A. Platz4,5 and Dominique S. Michaud1,7*

Abstract
Background: Examining immunity-related DNA methylation alterations in blood could help elucidate the role of the
immune response in lung cancer etiology and aid in discovering factors that are key to lung cancer development and
progression. In a nested, matched case–control study, we estimated methylation-derived NLR (mdNLR) and quantified DNA methylation levels at loci previously linked with circulating concentrations of C-reactive protein (CRP). We
examined associations between these measures and lung cancer risk and survival.
Results: Using conditional logistic regression and further adjusting for BMI, batch effects, and a smoking-based
methylation score, we observed a 47% increased risk of non-small cell lung cancer (NSCLC) for one standard deviation
(SD) increase in mdNLR (n = 150 pairs; OR: 1.47, 95% CI 1.08, 2.02). Using a similar model, the estimated CRP Scores
were inversely associated with risk of NSCLC (e.g., Score 1 OR: 0.57, 95% CI: 0.40, 0.81). Using Cox proportional hazards
models adjusting for age, sex, smoking status, methylation-predicted pack-years, BMI, batch effect, and stage, we
observed a 28% increased risk of dying from lung cancer (n = 145 deaths in 205 cases; HR: 1.28, 95% CI: 1.09, 1.50) for
one SD increase in mdNLR.
Conclusions: Our study demonstrates that immunity status measured with DNA methylation markers is associated
with lung cancer a decade or more prior to cancer diagnosis. A better understanding of immunity-associated methylation-based biomarkers in lung cancer development could provide insight into critical pathways.
Keywords: Lung cancer, DNA methylation, Methylation-based inflammation measures, C-reactive protein, mdNLR
Background
Lung cancer is the leading cause of cancer death in the
USA, projected to account for 21.7% of all cancer deaths
in 2021 [1]. A large percentage of lung cancer patients
are diagnosed at an advanced stage [2] and five-year relative survival rates for those patients are between 3 and
6% [3]. Thus, early detection remains a key strategy to
improve survival. However, the currently recommended
strategy for lung cancer screening—low-dose computed
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tomography (LDCT) for persons 50 to 80 years old with
at least a 20 pack-year smoking history and currently
smoke or have quit within the past 15 years—is expensive and has a high false positive rate [4, 5]. Modifying
the current lung cancer screening strategy by performing risk stratification could help prioritize LDCT screening and optimize secondary prevention. We propose that
immune system markers could be incorporated into such
risk stratification tools to help identify persons at higher
risk of lung cancer to target for screening.
While smoking is the most important risk factor for
lung cancer in the population, there is growing evidence
that the immune system, in response to or independent of smoking, plays an important role in lung cancer
development, acting potentially through the genesis of
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chronic inflammation [6]. For instance, an aggregated
genome-wide association studies (GWASs) analysis of
lung cancer risk found a direct causal effect of BMI on
small cell lung cancer and an inverse effect on lung
adenocarcinoma, suggesting the complexity of the role
BMI and chronic inflammation plays in lung cancer subtypes [7]. Furthermore, it is plausible that inflammatory
profiles prior to lung cancer diagnosis are associated
with lung cancer-specific survival. Markers of systemic
inflammation, including elevated levels of C-reactive protein (CRP) and the peripheral blood neutrophil-to-lymphocyte ratio (NLR), also have been identified as robust
markers of cancer-associated inflammation [8, 9]. Elevated CRP levels [8], elevated serum levels of pro-inflammatory cytokines [10–12], increased neutrophil counts
and decreased lymphocyte counts [13, 14], and polymorphisms in inflammation-related genes [15–18] have
been associated with increased lung cancer risk. These
inflammatory measures have also been associated with
poor survival of lung cancer patients in several retrospective and a few prospective studies [19–21]. In addition,
both experimental and epidemiologic studies support
a role for chronic inflammation as a hallmark of cancer
development and progression [8, 22–25]. We posit that
a better understanding of the role of inflammation in
lung cancer etiology could be gained by examining DNA
methylation alterations in blood that are associated with
the systemic immune response.
In the current study, we first predicted peripheral
blood leukocyte composition and a neutrophil to lymphocyte index using validated DNA methylation markers
(mdNLR), then quantified DNA methylation levels at loci
previously linked with circulating concentrations of CRP,
and calculated methylation-derived immune cell ratios by
using an expanded deconvolution library. We evaluated
the associations of these potential markers with lung cancer risk and lung cancer-specific survival. To address this
question, we used pre-diagnostic blood samples of cases
and controls obtained from the CLUE I/II cohorts. Our
analyses controlled for self-reported smoking and methylation-predicted cumulative smoking in order to better
focus our examinations on the DNA methylation marks
that are informative of the immune response profile [26].

Results
Population characteristics

Characteristics of the 208 lung cancer cases and their 208
matched controls included in this analysis are presented
in Table 1. Over 99% of the majority of participants were
White. The median time between blood draw and lung
cancer diagnosis was 14 years. The median age at blood
draw in 1989 was 59 and 57 years in cases and controls,
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respectively. Overall, 55% of cases and controls were
women and 11% were never smokers (Table 1).
Methylation‑derived mdNLR index, leukocyte proportions,
and lung cancer risk

We observed a 47% increased risk of non-small cell lung
cancer (NSCLC) for one standard deviation increase in
mdNLR (n = 150 pairs; OR: 1.47 [1.08, 2.02]). However,
higher mdNLR values were not statistically associated
with overall risk of lung cancer in our study. This association was comparable for NSCLC cases diagnosed
within 10 years and beyond 10 years after blood draw.
No stable associations could be estimated for small cell
lung cancer (SCLC). After multiple comparison adjustments, monocyte/lymphocyte ratio showed a borderline significant 65% increased risk of NSCLC for each
standard deviation increase (n = 150 pairs; OR: 1.65,
adjusted CI: [0.99, 2.76]). In addition, immune cell ratios
for CD4/CD8, NLR, B cell/lymphocyte, T cell/lymphocyte, Neu + Mono/lymphocyte, Eos/lymphocyte, CD4nv/
lymphocyte, B cell/CD8, CD8/Treg, Bnv/Bmem, CD4nv/
CD4mem, CD8nv/CD8mem, and Treg > 0 vs. Treg = 0
were not statistically significantly associated with lung
cancer risk overall or by histologic types (Table 2).
Methylation‑derived CRP scores and lung cancer risk

CRP Score 1 was built using 54 CpG sites that were previously associated with inflammatory markers, while CRP
Score 2 and 3 were each built with a subset of these 54
CpGs that were putative cell-specific or cell type invariant, respectively. Using data from a previously published
pancreatic cancer dataset [27], all three scores were
moderately correlated with log CRP and log IL-6 levels
(Table 3). In this nested case–control study, we found
all three CRP Scores inversely associated with risk of
NSCLC after additionally adjusting for methylation-predicted pack-years (n = 150 pairs; Score 1 OR: 0.57 [0.40,
0.81]; Score 2 OR: 0.62 [0.45, 0.84]; Score 3 OR: 0.65 [0.44,
0.95]). We also found statistically significant inverse association between CRP Score 1 and risk of NSCLC among
cases diagnosed within 10 years and beyond 10 years,
and between CRP Score 2 for NSCLC cases diagnosed
within 10 years of blood draw (Table 4). CRP Scores 1,
2, and 3 were not associated with lung cancer risk when
taking into account the matching factors and only adjusting for BMI and four surrogate variables for batch effects
(n = 208 pairs; Score 1 OR: 0.96 [0.77, 1.21]; Score 2 OR:
0.89 [0.71, 1.11]; Score 3 OR: 1.11 [0.89, 1.40]). However,
when additionally adjusting for methylation-predicted
pack-years, inverse associations with total lung cancer
risk were observed for Score 1 (OR: 0.76 [0.59, 0.99]) and
Score 2 (OR: 0.77 [0.61, 0.98]). We also observed a 33%
decreased risk of lung cancer for one standard deviation
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Table 1 Baseline characteristics of lung cancer cases and matched controls nested in CLUE I/II
Controls

Cases
All lung cancers

Non-small cell lung cancer Small cell lung cancer

N

208

208

150

Median age (range, years)

56 [28, 81]

59 [30, 83]

58 [36, 83]

53 [30, 71]

14 [0, 29]

14 [0, 28]

12 [2, 29]

Median time before diagnosis (range, years)

29

Sex
Male

95 (45.7%)

95 (45.7%)

61 (40.7%)

16 (55.2%)

Female

113 (54.3%)

113 (54.3%)

89 (59.3%)

13 (44.8%)

White

208 (100%)

205 (98.6%)

149 (99.3%)

28 (96.6%)

Black

0 (0%)

3 (1.4%)

1 (0.7%)

1 (3.4%)

Never smoker

22 (10.6%)

22 (10.6%)

15 (10.0%)

1 (3.4%)

Ever smoker

80 (38.5%)

80 (38.5%)

56 (37.3%)

10 (34.5%)

Current smoker

106 (51.0%)

106 (51.0%)

79 (52.7%)

18 (62.1%)

20 [0, 80]

20 [0, 80]

20 [0, 70]

20 [0, 80]

Never

176 (84.6%)

178 (85.6%)

132 (88.0%)

25 (86.2%)

Ever

28 (13.5%)

26 (12.5%)

15 (10.0%)

4 (13.8%)

Race

Cigarette smoking status

Median cigarette smoking Intensity (range, cig/
day)
Cigar or pipe smoking

Current

4 (1.9%)

4 (1.9%)

3 (2.0%)

0 (0%)

Median BMI, kg/m2 (range)

25.8 [18.0, 40.9]

25.6 [15.5, 42.6]

25.4 [15.5, 42.6]

25.6 [18.3, 34.7]

mdNLR mean (SD)

1.74 (0.976)

1.86 (1.32)

1.85 (1.19)

1.65 (1.07)

mdNLR median (range)

1.58 [0.13, 6.42]

1.59 [0.28, 11.90]

1.56 [0.28, 9.45]

1.44 [0.39, 4.81]

CRP score 1 mean (SD)

0.02 (1.01)
0.06 [− 2.42, 2.99]

− 0.04 (0.97)

0.47 (1.08)

CRP score 1 median (range)

− 0.02 (0.99)

CRP score 2 mean (SD)

0.04 (1.03)
0.01 [− 3.35, 3.93]

− 0.06 (0.95)

0.36 (1.17)

CRP score 2 median (range)

− 0.04 (0.98)

CRP score 3 mean (SD)

− 0.06 (0.98)

0.06 (1.02)

0.09 (1.03)

0.32 (0.97)

0.10 [− 2.34, 2.95]

0.38 [− 2.19, 1.97]

CRP score 3 median (range)

− 0.03 [− 3.26, 2.94] − 0.03 [− 3.26, 2.94]

0.41 [− 1.93, 2.16]

− 0.10 [− 2.68, 3.10] − 0.11 [− 2.68, 3.10]

0.24 [− 2.34, 3.10]

− 0.09 [− 2.43, 2.51] 0.08 [− 2.34, 2.95]

increase in CRP Score 1 (OR: 0.67 [0.47, 0.97]) among
those with time to diagnosis over 10 years.
Survival analysis

We examined whether the mdNLR, methylation-derived
immune cell ratios, and CRP Scores were associated with
risk of dying of lung cancer among lung cancer cases
(Table 5, Fig. 1).
We observed a 47% increased risk of dying for
one standard deviation of mdNLR for NSCLC cases
(n = 149 cases; HR: 1.47 [1.20, 1.81]). Among the
NSCLC cases whose mdNLR was from <  = 10 years
before their diagnosis, we found a 73% increased risk of
dying for a one standard deviation increase in mdNLR
(HR: 1.73 [1.19, 2.51]). In comparison, the risk of dying
for a one standard deviation increase in mdNLR was
lower among the NSCLC cases whose mdNLR was
from 10 to 25 years prior to diagnosis (HR: 1.39 [1.05,
1.85]). Lastly, we observed a 28% increased risk of dying

from lung cancer for one standard deviation increase
in mdNLR (n = 205 cases deleted 3 cases with personyear = 0 or > 25 years; HR: 1.28 [1.09, 1.50]).
Immune cell ratios for CD4/CD8, NLR, B cell/lymphocyte, T cell/lymphocyte, Mono/lymphocyte, Eos/
lymphocyte, CD4nv/lymphocyte, B cell/CD8, CD8/
Treg, Bnv/Bmem, CD4nv/CD4mem, CD8nv/CD8mem,
and Treg (> 0 vs = 0) were not associated with lung
cancer-specific death, except for a 48% increased risk
for one standard deviation increase in Neu + Mono/
lymphocyte ratio among the NSCLC cases (HR: 1.48
[1.04, 2.11]) and a borderline significant 29% increased
risk of dying from lung cancer (HR: 1.29, adjusted CI:
[1.00, 1.67]) for one standard deviation increase in
Neu + Mono/lymphocyte ratio after multiple comparison adjustments. Furthermore, the three CRP Scores
were not associated with lung cancer-specific death.
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Table 2 Association between methylation-predicted immune cell profiles and risk of total lung cancer and NSCLC risk, overall and
stratified by time to diagnosis, case–control study nested in the CLUE I/II cohort

mdNLRc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

CD4/CD8 Ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

B cell/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

T cell/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

Monocyte/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

(Neutrophil + monocyte)/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

Eosinophil/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

CD4 naïve/lymphocyte r atioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

B cell/CD8 r atioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

CD8/treg ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

Treg > 0 versus Treg = 0c

Time to diagnosis ≤ 10 years

All lung cancersa
OR (95% CI)

Non-small cell lung c ancerb
OR (95% CI)

1.11 (0.89, 1.38)

1.47 (1.08, 2.02)

0.97 (0.69, 1.35)

1.41 (0.90, 2.20)

1.22 (0.91, 1.64)

1.57 (0.98, 2.49)

1.17 (0.80, 1.72)

1.16 (0.74, 1.82)

0.94 (0.56, 1.57)

0.79 (0.38, 1.66)

1.47 (0.82, 2.62)

1.72 (0.77, 3.85)

1.07 (0.73, 1.57)

0.94 (0.58, 1.52)

1.16 (0.63, 2.14)

0.91 (0.42, 1.97)

0.98 (0.60, 1.59)

0.93 (0.50, 1.71)

1.06 (0.72, 1.56)

0.94 (0.60, 1.48)

1.11 (0.62, 1.98)

1.03 (0.49, 2.16)

1.05 (0.63, 1.76)

0.88 (0.48, 1.62)

1.15 (0.78, 1.69)

1.65 (0.99, 2.76)

1.18 (0.66, 2.11)

1.62 (0.75, 3.51)

1.16 (0.69, 1.94)

1.81 (0.86, 3.80)

1.13 (0.79, 1.61)

1.46 (0.87, 2.44)

0.96 (0.59, 1.56)

1.32 (0.67, 2.60)

1.26 (0.78, 2.04)

1.62 (0.80, 3.29)

0.94 (0.64, 1.38)

0.89 (0.53, 1.49)

0.81 (0.44, 1.49)

1.21 (0.48, 3.08)

1.01 (0.64, 1.59)

0.73 (0.36, 1.48)

1.22 (0.83, 1.80)

1.36 (0.84, 2.20)

1.47 (0.72, 2.99)

1.70 (0.74, 3.93)

1.11 (0.68, 1.80)

1.19 (0.67, 2.12)

0.97 (0.68, 1.38)

1.00 (0.66, 1.52)

1.06 (0.61, 1.83)

1.11 (0.58, 2.11)

0.85 (0.45, 1.62)

0.90 (0.44, 1.83)

0.81 (0.55, 1.19)

0.73 (0.45, 1.18)

0.86 (0.47, 1.59)

0.72 (0.33, 1.56)

0.78 (0.45, 1.35)

0.68 (0.33, 1.38)

1.05 (0.74, 1.50)

1.07 (0.70, 1.63)

0.95 (0.53, 1.70)

1.12 (0.55, 2.27)

Time to diagnosis > 10 years

1.10 (0.70, 1.73)

1.06 (0.61, 1.83)

B cell naïve/B cell memory r atioc

0.85 (0.58, 1.25)

0.87 (0.57, 1.32)

Time to diagnosis ≤ 10 years

0.65 (0.24, 1.76)

0.65 (0.21, 2.01)

Time to diagnosis > 10 years

0.93 (0.56, 1.56)

0.96 (0.56, 1.66)

CD4 naïve/CD4 memory r atioc

1.04 (0.73, 1.48)

1.59 (0.81, 3.13)

Time to diagnosis ≤ 10 years

0.98 (0.59, 1.64)

2.67 (0.65, 11.01)

Time to diagnosis > 10 years

1.18 (0.60, 2.32)

1.34 (0.58, 3.10)

CD8 naïve/CD8 memory r atioc

0.99 (0.72, 1.37)

1.01 (0.53, 1.92)

Time to diagnosis ≤ 10 years

0.66 (0.15, 2.81)

0.74 (0.17, 3.15)

1.04 (0.71, 1.53)

1.73 (0.36, 8.38)

Time to diagnosis > 10 years

Bold OR and CI values indicate statistical significance. Underline OR and CI values indicate borderline statistical significance after multiple comparison adjustment
a

208 cases and 208 controls matched on age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a
methylation-predicted pack-years smoked

b

150 cases and 150 controls matched on age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a
methylation-predicted pack-years smoked

c
OR results reported per 1 unit SD increase (mdNLR SD: 1.16; CD4/CD8 ratio SD: 2.07; BL ratio SD: 0.0526; TL ratio SD: 0.0802; ML ratio SD: 0.118; NM/L ratio SD: 1.22;
EL ratio SD: 0.0722; CD4nv/L ratio SD: 0.0915; B/CD8 ratio SD: 3.07; CD8/Treg ratio SD: 115; Bnv/Bmem ratio SD: 109; CD4nv/CD4mem ratio SD: 0.429; CD8nv/CD8mem
ratio SD: 2.05) and OR results reported for Treg > 0 versus 0; Bonferroni-adjusted CI reported for all except mdNLR (a prior hypothesis)
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Table 3 Correlations between methylation-based CRP scores and circulating log-CRP level, log-IL6 level, peripheral blood leukocyte
types, BMI, and smoking score residual among controls only
Score 1b

Score 2c

Score 3d

Spearman (p value)

Spearman (p value)

Spearman (p value)

Pancreatic cancer study (controls only)
Log-CRP levela

0.284 (4.27e−06)

0.247 (6.96e−05)

0.297 (1.56e−06)

Log-IL6 levela

0.213 (7.53e−04)

0.158 (1.32e−02)

0.203 (1.33e−03)

CLUE I/II (controls only)
CD4T

0.425 (1.65e−10)

0.359 (1.00e−07)

0.212 (2.13e−03)

CD8T

0.504 (8.78e−15)

0.461 (2.34e−12)

0.390 (5.74e−09)

NK

0.062 (3.70e−01)

0.175 (1.17e−02)

0.026 (7.09e−01)

B cell

0.103 (1.38e−01)

0.069 (3.23e−01)

− 0.467 (1.19e−12)

− 0.422 (2.24e−10)

− 0.027 (6.99e−01)

− 0.488 (7.66e−14)

− 0.449 (1.01e−11)

Neutrophils
Monocytes
mdNLR
BMI

− 0.292 (1.92e−05)

Methylation-predicted pack-years residuale
a

0.025 (7.22e−01)

0.475 (4.46e−13)

− 0.330 (1.17e−06)

0.070 (3.12e−01)

0.375 (2.43e−08)

− 0.264 (1.17e−04)

− 0.288 (2.38e−05)

− 0.281 (3.96e−05)

− 0.063 (3.68e−01)
0.632 (1.42e−24)

Correlations with log-CRP level and log-IL6 level were tested with a pancreatic cancer dataset[43]

b

CpG Score 1 is built using 54 CpG sites

c

CpG Score 2 is built using the top 10 highly cell-specific CpG sites

d

CpG Score 3 is built using the 10 modestly cell-specific CpG sites

e

We calculated a pack-years methylation score to represent pack-years smoked associated methylation alterations. This score correlates with gene expression changes
that are affected by smoking

Table 4 Association between methylation-based CRP scores and risk of total lung cancer and NSCLC risk, overall and stratified by time
to diagnosis, CLUE I/II cohort
All lung cancersa
OR (95% CI)
CRP Score 1c
Time to diagnosis ≤ 10 years

Time to diagnosis > 10 years
CRP Score 2d

Time to diagnosis ≤ 10 years

Time to diagnosis > 10 years
CRP Score 3e

Time to diagnosis ≤ 10 years

Time to diagnosis > 10 years

Non-small cell lung cancerb
OR (95% CI)

0.76 (0.59, 0.99)

0.57 (0.40, 0.81)

0.84 (0.56, 1.26)

0.57 (0.33, 0.97)

0.67 (0.47, 0.97)

0.53 (0.32, 0.88)

0.77 (0.61, 0.98)

0.62 (0.45, 0.84)

0.79 (0.54, 1.17)

0.49 (0.28, 0.85)

0.73 (0.53, 1.02)

0.68 (0.46, 1.00)

0.79 (0.58, 1.07)

0.65 (0.44, 0.95)

0.87 (0.53, 1.42)

0.64 (0.35, 1.18)

0.73 (0.49, 1.09)

0.62 (0.36, 1.05)

Bold OR and CI values indicate statistical significance
a

208 cases and 208 controls matched for age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a
methylation-predicted pack-years smoked

b

150 cases and 150 controls matched for age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a
methylation-predicted pack-years smoked. The matched pairs were kept within each stratum

c

CpG Score 1 is built using 54 CpG sites and OR results reported per 1 unit of SD of CpG Score 1 (SD 1)

d

CpG Score 2 is built using the top 10 highly cell-specific CpG sites and OR results reported per 1 unit of SD of CpG Score 2 (SD 1)

e

CpG Score 3 is built using the 10 modestly cell-specific CpG sites and OR results reported per 1 unit of SD of CpG Score 3 (SD 1)

Discussion
Our study prospectively assessed predicted immune cell
profiles using DNA methylation markers and examined
associations between previously identified DNA methylation markers of inflammation and lung cancer risk and

survival. Using pre-diagnostic blood samples of lung cancer cases and controls who participated in the CLUE I/II
cohorts [23], pre-diagnosis mdNLR was associated with
increased risk of NSCLC, and among cases, with total
lung cancer and NSCLC lung cancer-specific death. In
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Table 5 Association between immune cell ratios and methylation-based CRP scores and lung cancer-specific mortality among lung
cancer cases, CLUE I/II cohort

mdNLRc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

CD4/CD8 ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

B cell/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

T cell/lymphocyte ratioc
Time to diagnosis ≤ 10 years

All lung cancersa
HR (95% CI)

Non-small cell lung cancerb
HR (95% CI)

1.28 (1.09, 1.50)

1.47 (1.20, 1.81)

1.34 (1.01, 1.76)

1.73 (1.19, 2.51)

1.20 (0.98, 1.48)

1.39 (1.05, 1.85)

1.02 (0.76, 1.36)

1.07 (0.78, 1.48)

1.28 (0.79, 2.07)

1.29 (0.70, 2.38)

0.96 (0.65, 1.41)

1.03 (0.66, 1.62)

0.97 (0.73, 1.30)

1.06 (0.74, 1.51)

0.87 (0.50, 1.50)

0.99 (0.52, 1.89)

1.11 (0.75, 1.63)

1.18 (0.75, 1.85)

1.01 (0.78, 1.31)

0.95 (0.69, 1.31)

1.01 (0.62, 1.64)

0.94 (0.53, 1.68)

Time to diagnosis > 10 years

1.05 (0.69, 1.60)

0.91 (0.54, 1.52)

Monocyte/Lymphocyte Ratioc

1.16 (0.87, 1.55)

1.21 (0.85, 1.72)

1.45 (0.87, 2.43)

1.52 (0.80, 2.89)

Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

(Neutrophil + monocyte)/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

Eosinophil/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

CD4 naïve/lymphocyte ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

B cell/CD8 ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

CD8/treg ratioc
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

1.25 (0.80, 1.96)

1.54 (0.84, 2.84)

1.29 (1.00, 1.67)

1.48 (1.04, 2.11)

1.36 (0.87, 2.13)

1.76 (0.95, 3.24)

1.22 (0.86, 1.74)

1.41 (0.87, 2.29)

1.01 (0.76, 1.35)

0.86 (0.60, 1.23)

1.55 (0.93, 2.59)

1.40 (0.74, 2.67)

0.98 (0.67, 1.44)

0.77 (0.49, 1.21)

0.92 (0.67, 1.27)

0.95 (0.65, 1.40)

0.92 (0.53, 1.59)

0.73 (0.35, 1.53)

0.91 (0.60, 1.38)

0.99 (0.61, 1.60)

1.03 (0.82, 1.29)

1.07 (0.83, 1.38)

1.01 (0.69, 1.49)

1.04 (0.64, 1.69)

1.05 (0.71, 1.55)

1.20 (0.74, 1.95)

0.92 (0.67, 1.27)

0.92 (0.63, 1.35)

0.73 (0.42, 1.26)

0.63 (0.30, 1.32)

1.03 (0.66, 1.62)

1.09 (0.63, 1.88)

0.96 (0.72, 1.28)

0.91 (0.64, 1.30)

Time to diagnosis ≤ 10 years

1.27 (0.76, 2.13)

1.37 (0.70, 2.69)

Time to diagnosis > 10 years

0.85 (0.58, 1.25)

0.75 (0.45, 1.26)

B cell naïve/B cell memory Ratioc

1.09 (0.84, 1.41)

1.23 (0.89, 1.70)

Time to diagnosis ≤ 10 years

1.31 (0.86, 1.99)

1.66 (0.74, 3.71)

Time to diagnosis > 10 years

1.03 (0.75, 1.42)

1.19 (0.73, 1.93)

CD4 naïve/CD4 memory ratioc

0.97 (0.70, 1.34)

1.03 (0.70, 1.52)

Time to diagnosis ≤ 10 years

0.91 (0.53, 1.57)

0.71 (0.32, 1.59)

Time to diagnosis > 10 years

1.00 (0.64, 1.57)

1.17 (0.70, 1.96)

CD8 naïve/CD8 memory ratioc

0.96 (0.70, 1.32)

1.10 (0.77, 1.57)

Time to diagnosis ≤ 10 years

1.09 (0.63, 1.88)

1.19 (0.59, 2.42)

Treg > 0 versus treg = 0c

Time to diagnosis > 10 years

CRP Score 1cd
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

CRP Score 2cd
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

0.92 (0.61, 1.40)

1.05 (0.67, 1.65)

0.92 (0.67, 1.26)

0.88 (0.60, 1.30)

1.00 (0.57, 1.75)

1.22 (0.67, 2.22)

1.04 (0.67, 1.63)

0.82 (0.46, 1.46)

0.86 (0.65, 1.13)

0.98 (0.69, 1.41)

0.76 (0.47, 1.23)

1.11 (0.61, 2.03)

1.10 (0.73, 1.66)

0.93 (0.55, 1.56)

Zhao et al. Clinical Epigenetics

(2021) 13:222

Page 7 of 12

Table 5 (continued)

CRP Score 3cd
Time to diagnosis ≤ 10 years
Time to diagnosis > 10 years

All lung cancersa
HR (95% CI)

Non-small cell lung cancerb
HR (95% CI)

1.05 (0.76, 1.47)

1.07 (0.73, 1.59)

1.01 (0.56, 1.81)

1.01 (0.46, 2.22)

1.16 (0.74, 1.83)

1.22 (0.69, 2.16)

Bold HR and CI values indicate statistical significance. Underline HR and CI values indicate borderline statistical significance after multiple comparison adjustment
a

205 cases (3 cases with person-year = 0 or > 25 years were removed from the analytical dataset) Model adjusted for age at blood draw, sex, smoking status, BMI,
surrogate variables for batch effects, and a pack-year-based smoking methylation score. The results for Inflammation Scores additional adjust for cell proportions. BMI
was removed from model when stratified by BMI. Group person-year: all lung cancer cases = 421.3; cases with time to diagnosis ≤ 10 years = 104.3; cases with time to
diagnosis > 10 years = 316.9; cases with BMI < 25 kg/m2 = 184.3; cases with BMI ≥ 25 kg/m2 = 236.9

b

149 cases (1 case with person-year =  >25 years were removed from the analytical dataset) Model adjusted for age at blood draw, sex, smoking status, BMI, surrogate
variables for batch effects, and methylation-predicted pack-years smoked. The results for Inflammation Scores additional adjust for cell proportions. BMI was removed
from model when stratified by BMI. Group person-year for all non-small cell lung cancer (NSCLC) cases = 337.6; NSCLC cases with time to diagnosis ≤ 10 years = 84.4;
NSCLC cases with time to diagnosis > 10 years = 253.2; NSCLC cases with BMI < 25 kg/m2 = 141.4; NSCLC cases with BMI ≥ 25 kg/m2 = 196.2

c
HR results reported per 1 unit of SD increase among all cases (mdNLR SD: 1.86; CD4/CD8 ratio SD: 2.14; BL ratio SD: 0.0534; TL ratio SD: 0.0844; ML ratio SD: 0.125;
NM/L ratio SD: 1.38; EL ratio SD: 0.079; CD4nv/L ratio SD: 0.0920; B/CD8 ratio SD: 2.21; CD8/Treg ratio SD: 112; Bnv/Bmem ratio SD: 81.3; CD4nv/CD4mem ratio SD:
0.335; CD8nv/CD8mem ratio SD: 1.64; CpG Score 1 SD: 0.979; CpG Score 2 SD: 0.945; CpG Score 3 SD: 1.02) and HR results reported for Treg > 0 versus Treg = 0 among
all cases; Bonferroni-adjusted CI reported for all except mdNLR and CRP Scores 1–3 (a prior hypotheses)
d

CpG Scores 1, 2, and 3 are built using 54 CpG sites, the top 10 highly cell-specific CpG sites, and the 10 modestly cell-specific CpG sites, respectively

Fig. 1 Survival curves for lung cancer-specific mortality
among lung cancer cases in the mdNLR high and low groups
(> or ≤ 75% quartiles). Plot adjusted for age, sex, smoking status,
methylation-predicted pack-years smoked, BMI, stage, and batch
effects

addition, we built a series of methylation-derived CRP
scores to capture individual systemic inflammatory profiles years before lung cancer diagnosis; these scores were
inversely associated with risk of lung cancer, especially
for NSCLC after adjusting for methylation-predicted
pack-years smoked, but not with lung cancer-specific
mortality.
Studies on NLR (calculated from measured WBC differentials) and lung cancer risk and survival typically
measure pre-treatment NLR at diagnosis or up to 30 days
prior to treatment [28–30]. Unlike prior studies, we were
able to assess individual systemic inflammation profiles many years prior to diagnosis by using methylation

markers of inflammation. Our study is not directly comparable to prior studies since we measured mdNLR using
blood samples from subjects with a median of 14 years
prior to lung cancer diagnosis. In addition, most cases
in our study were diagnosed before the widespread use
of immunotherapy. To our knowledge, only one other
cohort, the multicenter β-Carotene and Retinol Efficacy
Trial (CARET), examined pre-diagnosis mdNLR and
lung cancer risk and survival using blood drawn years
prior to diagnosis (median 4.7 years) [31, 32]. CARET, a
study of heavy smokers, reported a 21% increased risk of
lung cancer per one unit increase in mdNLR (OR: 1.21
[1.01, 1.45]), a 30% increased risk of NSCLC for one unit
increase in mdNLR (OR: 1.30 [1.03, 1.63], and no association between higher pre-diagnosis mdNLR and risk
of developing SCLC (OR: 1.06 [0.77, 1.47]) [31]. Like in
CARET, in CLUE I/II we observed a 47% increased risk of
NSCLC for a one standard deviation increase in mdNLR
(n = 150 pairs; OR: 1.47 [1.08, 2.02]), but in contrast to
CARET, we found no statistically significant association
for overall lung cancer risk.
CARET researchers recently reported that pre-diagnosis mdNLR was positively associated with increased
mortality for SCLC cases, but not for other case types
[32]. In comparison, we observed a positive association
between pre-diagnosis mdNLR and lung cancer-specific
and NSCLC-specific mortality. In the case of SCLC, the
number of cases was too limited for us to estimate stable associations (N = 29). Taken together, the CLUE and
CARET results suggest that a systemic inflammatory
profile marked by elevated NLR could indicate a lesser
ability to mount a robust immune response to a developing lung cancer and/or a more favorable environment for

Zhao et al. Clinical Epigenetics

(2021) 13:222

cancer progression. Differences in findings between the
two studies could stem from differences in study populations. The CARET cohort is exclusively heavy smokers,
including a subgroup exposed to asbestos. In comparison, our analysis in the CLUE I/II cohorts included never,
ever, and current smokers. Furthermore, our study population had a lower mdNLR in the lung cancer cases (mean
1.86 and SD 1.32) than in CARET (mdNLR mean 2.18
and SD 1.46).
Using a newly expanded deconvolution library, we were
able to parse apart the granulocyte subtypes (neutrophils,
eosinophils, and basophils) and investigate the balance
between naïve and memory cell compartments for lung
cancer. Previous research has identified the monocyte/
lymphocyte (or lymphocyte/monocyte) ratio as an independent prognostic factor in NSCLC, demonstrating significant association with overall survival in patients with
NSCLC [33–35]. In comparison, our exploratory analyses
of immune cell ratios suggest that one standard deviation increase in the monocyte/lymphocyte ratio could
potentially indicate increased risk of NSCLC after additionally adjusting for methylation-predicted pack-years.
In addition, we found an increased risk of dying from
lung cancer associated with an increase in Neu + Mono/
lymphocyte ratio among the NSCLC cases after multiple
comparison adjustments.
We also investigated three CRP Scores that we built
from 54 CpG sites that had been strongly associated with
CRP in previous studies. We found these methylationpredicted CRP Scores to be moderately correlated with
log-CRP and log-IL6 in the controls of a previously published pancreatic cancer dataset [27]. CRP is a systemic
marker of chronic inflammation and has been reported
as a risk factor for cancer development [36]. Previous
studies of pre-diagnostic circulating CRP concentration and lung cancer risk (7 cohorts [10, 11, 19, 37–39]
and 3 nested case–control studies [8, 12, 40]) have consistently found a moderate positive association between
pre-diagnostic CRP concentrations and lung cancer
risk. In our study, CRP Scores were not associated with
lung risk when taking into account the matching factors,
BMI, and batch effects. However, we observed an inverse
association when additionally adjusting for methylationpredicted pack-year. Our results suggest that when strict
control of smoking is applied, our CRP Score is likely
capturing the unique individual immune response that is
not driven by smoking.
Furthermore, these results provide preliminary evidence supporting the hypothesis that systemic inflammation not driven by smoking could have a protective effect
on individuals. While smoking is by far the most important risk factor for lung cancer, our DNA methylationbased CRP Scores provide the opportunity to examine
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inflammatory measures not related to smoking that
could play a role in modulating cancer risk years prior
to diagnosis. Lastly, our experience with the CRP Scores
suggests that measuring methylation-derived inflammatory responses using pre-diagnostic samples provides the
opportunity to capture informative individual systemic
inflammatory profiles years prior to diagnosis, potentially
shedding light on risk factors key to lung cancer development and progression, e.g., underlying genetics, exposure
to environmental risk factors, and behavior risk factors.
Like other observational studies, our study included
a limited number of NSCLC and SCLC cases. The relatively small sample size of SCLC cases (N = 29) impacted
our ability to observe associations for this subtype (SCLC
comprises about 15% of lung cancer cases in the USA). In
our survival analysis, we adjusted for stage and restricted
our analysis to samples whose time between blood draw
and date of lung cancer diagnosis was less than 25 years;
however, our survival analysis did not have access to
post-diagnosis smoking status information. Our study is
also limited by a lack of replication dataset and reduced
generalizability. (Study population is mainly White and
with very few cases in never smokers.) The CRP Scores
we built should be investigated in other populations to
ensure that what we observed did not arise due to chance.

Conclusions
Our study suggests that elevated pre-diagnosis mdNLR
and a lower non-smoking-related systemic inflammatory
profile before diagnosis are associated with higher cancer risk and poorer lung cancer-specific survival. These
relationships were especially evident for NSCLC. As
the most common subtype of lung cancer, most NSCLC
cases are diagnosed with locally advanced or metastatic
disease. Our prospective results support future evaluation of whether DNA methylation-based inflammatory
measures could enhance lung cancer risk stratification to
improve targeted lung cancer screening.
Methods
Study Population

This nested case–control study selected cases and controls from individuals who participated and provided
blood in both CLUE I and CLUE II [26]. The CLUE I
cohort was developed to identify serologic precursors
of cancer and was conducted in Washington County,
Maryland, in the fall of 1974. A blood sample was collected from 25,620 volunteers at the time of participation
[41, 42]. The CLUE II cohort was conducted from May
through October 1989. During this time, 32,894 participants donated a blood sample which was collected
in tubes containing heparin and kept chilled until centrifuged, aliquoted into plasma, erythrocytes, and buffy
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coat, and frozen at 70 °C [43]. In CLUE II, the baseline for
this study, health information was collected at the time
of blood draw, including attained education, cigarette
smoking status, cigarette smoking dose, cigar/pipe smoking status, and self-reported weight and height.
Incident lung cancer cases were ascertained from linkage to the Washington County cancer registry (before
1992 to the present) and the Maryland Cancer Registry
(since 1992 when it began to the present). We ascertained 241 incident lung cancer cases who participated in
CLUE I and were diagnosed after the day of blood draw
in CLUE II through January 2018. Cases were characterized with respect to histology. We used incidence density sampling to select one control matched to each case
on age, sex, smoking status and intensity (cig/day), and
cigar/pipe smoking status. Death from lung cancer as the
underlying cause was obtained from death certificates.
The Institutional Review Board at the Johns Hopkins
Bloomberg School of Public Health and the Tufts University Health Sciences Campus Institutional Review Board
approved this study.
DNA methylation measurements

Extracted DNA was bisulfite-treated using the EZ DNA
Methylation Kit (Zymo), and DNA methylation was
measured with the 850 K Illumina Infinium MethylationEPIC BeadChip Arrays (Illumina, Inc., CA, USA).
All samples and all array experiments were performed
blinded to case–control status. Details on DNA methylation measurements, data preprocessing processing,
and quality control assessment/screening are provided
in the Additional file 1. The 850 K methylation microarray has been validated from a biological and technical
standpoint. Reproducibility of results from 850 K Illumina array has been previously shown to be very high
(r = 0.997) [44]. DNA volume and quality were sufficient for 208 of the cases and 222 controls totaling 208
matched pairs.
Estimation of peripheral blood leukocyte composition

Peripheral blood leukocyte subtypes proportions, including myeloid lineage sub-types [neutrophils (Neu), eosinophils (Eos), basophils (Bas), and monocytes (Mono)]
and lymphoid lineage subtypes [B lymphocytes naïve
(Bnv), B lymphocytes memory (Bmem), T helper lymphocytes naïve (CD4nv), T helper lymphocytes memory
(CD4mem), T regulatory cells (Treg), T cytotoxic lymphocytes naïve (CD8nv), T cytotoxic lymphocytes memory (CD8mem), and natural killer lymphocytes (NK)],
were estimated using a newly expanded reference-based
deconvolution library EPIC IDOL-Ext [45]. This library
used the IDOL methodology [46] to optimize the currently available six-cell reference library [47] in order
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to deconvolve the proportions of 12 leukocyte subtypes
in peripheral blood. This EPIC IDOL-Ext library (Bioconductor package FlowSorted.BloodExtended.EPIC)
was validated using flow cytometry gold standard data
and substantiated by including publicly available data
from > 100,000 samples [45].
Methylation‑Derived Neutrophil Lymphocyte Ratio
(mdNLR)

The peripheral blood neutrophil-to-lymphocyte ratio
(NLR) is a cytological marker of both inflammation and
poor outcomes in cancer patients [48–52]. We used a
DNA methylation-derived NLR (mdNLR) index to predict the common clinical NLR parameter using a previously described approach [9]. This index is based on
normal isolated leukocyte reference DNA methylation
libraries and established reference-based cell mixture
deconvolution algorithms [9, 53].
Inflammation‑associated CpG score

We used 54 CpG sites that have been strongly associated
with C-reactive protein (CRP) [54, 55] to build three CRP
Scores. We selected these 54 CpGs (remaining 4 were not
on the 850 K array that we used) from the 58 CpGs identified by Ligthart and colleagues [54] for their association
with serum CRP level (listed in Table 3) using 450 K DNA
methylation data. Forty-five of these 58 CpG sites were
validated to have the same direction of protein–methylation associations by Myte et al. [55]. These CpGs, while
identified based on their CRP association, have also been
shown to be associated with other inflammatory mediators [54–56]. To compute CRP Score 1, we multiplied the
beta value at each selected CpG site with the effect size
estimates reported by Ligthart et al. These estimated beta
coefficients represented the change in DNA methylation
per one unit increase in log CRP. In the CRP Score 1 formula, we weighted the beta coefficients estimated by Ligthart et al. with their corresponding standard errors.

CRP Scorei =



Bij ×

j
SEj

Bij is the beta value for the ith participant at the jth CpG
site. ∆j is the beta coefficients reported by Ligthart et al.
for the jth CpG site. SEj is the SE reported by Ligthart
et al. for the jth CpG site.
Since most of the estimated beta coefficients are negative, CRP Score 1 ranged between − 0.059 and -0.026 in
these participants. A score closer to zero indicated higher
CRP levels. Based on CRP Score 1, we computed two
additional CRP Scores, one cell (leukocyte)-type invariant (CRP Score 2) and one cell-specific (CRP Score 3).
Among the 54 inflammation (CRP)-associated CpGs, we
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identified putative cell-type invariant and cell-specific
CpGs by conducting ANOVA using the dataset described
in Salas and Koestler et al. [47] and publicly available
on the Gene Expression Omnibus (GSE110555). The
dataset used for this ANOVA consisted of EPIC methylation data profiled in purified leukocyte cell population isolated from different healthy adults. Specifically,
methylation signatures were available for CD4 + T cells,
CD8 + T cells, NK cells, B cells, monocytes, and neutrophils. One-way ANOVA models were fit independently
to each of the 54 CRP-associated CpGs treating methylation as the dependent variable and cell type as the independent variable. We tested the null hypothesis that the
mean methylation beta-value is the same across the cell
types. The F-statistic, corresponding p value, and maximum absolute pairwise difference in the mean methylation beta value across cell types were calculated for each
of the 54 CpGs. We then selected subgroups of CpG sites
that had the top 10 smallest or top 10 largest F-statistic
value to build the two additional CRP Scores. CRP Score
2 consists of putative cell-specific CpGs with high F-statistics, e.g., those exhibiting a difference in mean methylation beta-values between at least two of the six cell
types. CRP Score 3 is made of cell-type invariant CpGs
with low F-statistics, e.g., CpGs for which there did not
appear to be a substantial difference in mean methylation
beta-values across the normal six leukocyte subtypes.
Score 2 ranged between − 0.0002 and 0.0046, while Score
3 ranged between − 0.025 and − 0.016. In the regression
analyses, we used a standardized version of CRP Scores
1, 2, and 3 (mean = 0, sd = 1) for easier interpretation of
results and allowing us to compare the results for each of
the scores.
Statistical analyses

All statistical analyses were performed in R (version
3.5.1). We estimated mdNLR as described above, used an
independent pancreatic cancer dataset [27] to estimate
the correlation between estimated values of CRP Scores
1–3 with the log CRP and log IL-6 levels, and tested a
series of a priori hypotheses concerning the mdNLR and
CRP Scores. In addition, we also conducted exploratory
analyses to generate novel hypotheses regarding the role
of methylation-derived leukocyte proportions in lung
cancer. Immune cell ratios (e.g., CD4/CD8, Neu/lymphocyte, B cell/lymphocyte, T cell/lymphocyte, Mono/
lymphocyte, Neu + Mono/lymphocyte, Eos/lymphocyte, CD4nv/lymphocyte, B cell/CD8, CD8/Treg, Bnv/
Bmem, CD4nv/CD4mem, and CD8nv/CDmem) were
calculated for each sample by taking the ratio of its predicted cell proportions described above and tested as
continuous variables. The presence of Treg was tested
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as a dichotomous variable. Given the need for multiple
comparison adjustment, Bonferroni adjustment (familywise error rate = 0.0013) was conducted for all exploratory analyses.
We used conditional logistic regression to examine the
association between DNA methylation-based inflammatory measures (CRP Scores 1–3 and continuous mdNLR)
and lung cancer risk. Models were fit with age, sex, and
smoking status (never, former, current) as matching factors and were adjusted for potential confounding factors, including body mass index (BMI), batch effect, and
previously described methylation-predicted pack-years
smoked [57]. These analyses did not additionally adjust
for methylation-derived cell proportions given how these
proportions correlated with methylation-based inflammatory measures (Table 3). We repeated these analyses
by lung cancer histology (NSCLC, SCLC), length of time
between blood draw and diagnosis (< = 10, > 10 years),
and BMI (< 25, ≥ 25 kg/m2).
Among the lung cancer cases, we examined the association between these same pre-diagnostic DNA methylation-based inflammatory measures (CRP Scores 1–3
and continuous mdNLR) and risk of lung cancer-specific
death using a series of multivariable Cox proportional
hazard regression adjusting for age, gender, smoking
status, BMI, stage at diagnosis (three strata: stage 1 & 2,
stage 3 & 4, and missing), cell proportion, batch effects,
and methylation-predicted pack-years smoked. The proportional hazards assumption was checked by conducting global tests of correlating the set of scaled Schoenfeld
residuals with time for each covariate. We excluded three
lung cancer cases whose date of diagnosis and date of
death were the same, or whose time between blood
draw and date of lung cancer diagnosis was longer than
25 years. Cases were followed until their date of death
from lung cancer, death from another cause, or the end of
follow up in 2018, whichever came first.
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